title: Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both.
abstract: OBJECTIVE
  To stratify MI risk reduction in those treated with a TNF inhibitor for psoriasis only, psoriatic arthritis only, or both psoriasis and psoriatic arthritis.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Between January 1, 2004 and November 30, 2010.
  
  
  METHODS
  At least 3 ICD9 codes for psoriasis (696.1) or psoriatic arthritis (696.0) (without antecedent MI.
  
  
  METHODS
  None
  
  
  METHODS
  Incident MI.
  
  
  RESULTS
  When comparing to those not treated with TNF inhibitors (reference group), of those treated with TNF inhibitors: those with psoriasis only (N= 846) had a significant decrease in MI risk (hazard ratio (HR), 0.26; 95% CI, 0.12-0.56); those with psoriatic arthritis only (N= 112) had a non-significant decrease in MI risk (HR, 0.86; 95% CI, 0.28-2.70); those with both psoriasis and psoriatic arthritis (N= 715) had a non-significant decrease in MI risk (HR, 0.76; 95% CI, 0.47-1.24).
  
  
  CONCLUSIONS
  In the TNF inhibitor cohort, those with psoriasis only have the strongest association with MI risk reduction, followed by those with psoriatic arthritis only, and then followed by those with both psoriasis and psoriatic arthritis.
authors.forename: Jashin J
authors.initials: JJ
authors.lastname: Wu
authors.forename: Kwun-Yee T
authors.initials: KY
authors.lastname: Poon
mesh_terms: D000328:Adult; D002140:California / Q000453:epidemiology; D015331:Cohort Studies; D016208:Databases, Factual; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000517:prevention & control; D011243:Preferred Provider Organizations / Q000706:statistics & numerical data; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D012306:Risk; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha